Group 1 - The article emphasizes the passion for investing, dividends, frugality, and passive income as a pathway to financial freedom [1] - It highlights the importance of reinvesting dividends to achieve a work-free life [1] - The company shares updates on stocks being monitored, bought, and sold, along with overall market thoughts [1] Group 2 - The company maintains an active presence on various platforms including a blog, social media, and a YouTube channel to engage with followers [1] - The content shared includes every aspect of their investment journey, aiming to provide transparency and insights [1]

Core Insights - AbbVie has launched the second annual AbbVie Migraine Career Catalyst Award™ contest, providing financial support to individuals living with migraine to pursue their personal, professional, and educational goals [1][5][8] - The contest aims to raise awareness about the impact of migraine in the workplace, where it is often misunderstood, and to advocate for individuals affected by this condition [2][3][9] Group 1: Contest Details - The contest is open for entries until September 2, 2025, with 20 winners receiving $2,500 each [1][5][6] - Participants can submit essays, videos, or audio clips detailing their experiences with migraine and career aspirations [4][5] - Winners from the previous year utilized their awards for various professional development activities, such as creating migraine-friendly workspaces and enhancing their skills [3][4] Group 2: Impact of Migraine - Migraine is the second leading cause of disability globally, significantly affecting productivity and career growth [2][8] - Nearly 90% of individuals with migraine report that it interferes with their work performance, highlighting the need for support beyond medical treatment [2][8] - AbbVie is the only company with three approved migraine treatment products and is committed to addressing the challenges faced by individuals living with migraine in professional settings [9][10]

Group 1 - AbbVie will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, with management engaging in a fireside chat at 10:20 a.m. Central time [1] - A live audio webcast of the presentation will be available on AbbVie's Investor Relations website, with an archived version accessible later that day [1] Group 2 - AbbVie's mission focuses on discovering and delivering innovative medicines and solutions to address serious health issues and future medical challenges [2] - The company aims to make a significant impact in key therapeutic areas including immunology, oncology, neuroscience, and eye care, along with products in the Allergan Aesthetics portfolio [2]

Core Insights - Bitcoin (BTC-USD) has increased by 55% and Gold (GLD) by 40% over the past 12 months, indicating a strong market interest in scarce assets [2] Group 1: Investment Focus - iREIT+HOYA Capital emphasizes income-producing asset classes that provide sustainable portfolio income, diversification, and inflation hedging [1] Group 2: Market Trends - The significant rallies in Bitcoin and Gold suggest a growing preference for assets perceived as scarce, reflecting broader market trends [2]

Core Points - AbbVie has launched a multi-year partnership with the Chicago Cubs to support cancer advocacy through the "Striking Out Cancer" campaign, which begins with the Cubs' game against the Cincinnati Reds [1][3] - For every strikeout by a Cubs pitcher at home during the 2025 regular season, AbbVie will donate $233, reflecting the statistic of approximately 233 Americans diagnosed with cancer every hour [1][2] - The funds raised will be donated to Cubs Charities, benefiting non-profit organizations like Conquer Cancer®, which focuses on advancing cancer research and patient care [1][3][7] Company Overview - AbbVie is a global biopharmaceutical company dedicated to discovering and delivering transformative medicines across various therapeutic areas, including oncology [2][4] - The company aims to address serious health issues and improve patient outcomes through innovative therapies for cancers such as leukemias, lymphomas, and lung cancer [2][4] Partner Overview - The Chicago Cubs, a historic Major League Baseball franchise, have a commitment to community engagement and charitable initiatives, including the "Striking Out Cancer" campaign [5][6] - Cubs Charities has invested over $51 million in community programs since 2009, focusing on youth development and safe play environments [6] Beneficiary Overview - Conquer Cancer®, the ASCO Foundation, has awarded over $203 million in grants to improve cancer care and research since its inception in 1984 [7]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have artificially deflated the stock price prior to a merger announcement with AbbVie Inc. [1][4] Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes shareholders who sold or held shares during this timeframe [3]. - Shareholders are encouraged to register for the class action by June 3, 2025, to potentially be appointed as lead plaintiffs [5]. Group 2: Allegations Against Cerevel - The complaint alleges that Cerevel's October 16, 2023 secondary stock offering documents omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [4]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [4]. Group 3: Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case's status [5]. - There is no cost or obligation for shareholders to participate in the class action [5].

Core Viewpoint - AbbVie is navigating challenges from the loss of exclusivity of its blockbuster drug Humira, but it is successfully replacing its revenue with new drugs Skyrizi and Rinvoq, which are showing strong sales growth and have a promising pipeline ahead [4][10][20]. Group 1: Stock Performance and Market Conditions - AbbVie stock has declined 12.6% over the past three months and is trading below its 50-day and 200-day moving averages, largely due to broader macroeconomic uncertainties [1] - The U.S. and China have imposed high tariffs that have negatively impacted global stock markets, although these tariffs are currently on pause, the uncertainty remains [2] - AbbVie has outperformed the industry and the S&P 500 index, gaining 5% so far this year compared to a 3% decrease for the industry [12][14] Group 2: Product Performance - AbbVie lost patent protection for Humira, leading to a significant decline in its sales, which dropped almost 50% in Q1 2025 due to biosimilar competition [4][10] - Skyrizi and Rinvoq generated combined sales of $5.1 billion in Q1 2025, reflecting over 65% growth, particularly strong in the inflammatory bowel disease market [5][6] - AbbVie expects combined sales of Skyrizi and Rinvoq to reach approximately $24.7 billion in 2025 and over $31 billion by 2027, driven by market share gains and new indications [6] Group 3: Pipeline and Acquisitions - AbbVie has a robust pipeline with several early/mid-stage candidates that have blockbuster potential, expecting multiple regulatory submissions and approvals in the next 12 months [7] - The company has been active in acquisitions, signing over 20 early-stage deals since early 2024, enhancing its pipeline in immunology, oncology, and neuroscience [9] - AbbVie is entering the obesity treatment market with the acquisition of rights to develop GUB014295, marking its expansion into a new therapeutic area [9] Group 4: Future Outlook - AbbVie anticipates a return to robust revenue growth in 2025, driven by its ex-Humira platform, which saw over 21% sales growth in Q1 2025 [20] - The company expects mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029, supported by strong performances from Skyrizi and Rinvoq [21] - Rising earnings estimates and a solid pipeline provide a favorable outlook for AbbVie, making it a stock to consider for long-term investment [22]

Group 1 - The article promotes iREIT on Alpha as a source for in-depth research on various income alternatives including REITs, mREITs, Preferreds, BDCs, MLPs, and ETFs, highlighting its positive testimonials [1] - It mentions a free 2-week trial for new users, suggesting a low-risk opportunity to access detailed investment research [1] Group 2 - The article includes a disclosure from an analyst indicating a long position in shares of LMT and ABBV, emphasizing personal opinions and lack of compensation from mentioned companies [2] - It clarifies that past performance does not guarantee future results and that no specific investment advice is provided [3]

Group 1 - The Dividend Aristocrats are underperforming compared to the S&P 500, trailing the index in both April and May [1] - As of May 23rd, the ProShares S&P 500 Dividend Aristocrat ETF (NOBL) has increased by 0.84% [1]

Core Insights - AbbVie is showcasing significant advancements in its oncology portfolio at the upcoming ASCO Annual Meeting, highlighting investigational antibody-drug conjugates (ADCs) targeting various difficult-to-treat cancers [2][3]. Group 1: Key Data Presentations - The investigational ADC telisotuzumab adizutecan (ABBV-400, Temab-A) demonstrated a 63% objective response rate (ORR) in a Phase 1 study involving 41 patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) [3][4]. - ABBV-706, another ADC targeting high-grade neuroendocrine neoplasms (NENs), showed a 31.3% ORR in a Phase 1 study with a median duration of response (DoR) of 5.6 months [4]. - Pivekimab sunirine (PVEK) achieved a 70% composite complete response (CCR) rate in untreated patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA trial [4][5]. Group 2: Ongoing Clinical Trials - Telisotuzumab adizutecan is being evaluated in multiple ongoing trials, including a Phase 1/2 study in first-line NSCLC and a Phase 3 study in refractory metastatic colorectal cancer [3]. - ABBV-706 is under investigation as monotherapy and in combination with other therapies for advanced solid tumors expressing SEZ6 [4]. - Pivekimab sunirine is also being studied in a Phase 1/2 trial for relapsed/refractory acute myeloid leukemia [5]. Group 3: Company Commitment and Strategy - AbbVie emphasizes its commitment to transforming cancer care through targeted therapies and biomarker-driven approaches, reflecting a significant expansion of its ADC portfolio [6][14]. - The company is advancing over 35 investigational medicines across various cancer types, aiming to address unmet medical needs in oncology [15].